Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 18, Pages 9783
Publisher
MDPI AG
Online
2021-09-10
DOI
10.3390/ijms22189783
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
- (2021) Suzanne Carreira et al. Cancer Discovery
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Zhen Shi et al. JOURNAL OF CLINICAL ONCOLOGY
- An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer
- (2020) Nancy A. Dawson et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
- (2020) Stergios Boussios et al. Drugs in research & development
- Molecular Trajectory of BRCA1 and BRCA2 Mutations
- (2020) Yuichiro Hatano et al. Frontiers in Oncology
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
- (2020) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibitor resistance: the underlying mechanisms and clinical implications
- (2020) He Li et al. Molecular Cancer
- Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
- (2020) Miriam Kokal et al. Cancers
- An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
- (2020) Helen Saxby et al. Diagnostics
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Characterizing CDK12-Mutated Prostate Cancers
- (2020) Pasquale Rescigno et al. CLINICAL CANCER RESEARCH
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
- (2020) William T. Lowrance et al. JOURNAL OF UROLOGY
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II
- (2020) William T. Lowrance et al. JOURNAL OF UROLOGY
- BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
- (2020) Carlo Messina et al. Journal of Oncology
- Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
- (2020) Daniel Harrision et al. Frontiers in Molecular Biosciences
- Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
- (2020) Stergios Boussios et al. Annals of Translational Medicine
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Pan‐Cancer Analysis of CDK12 Loss‐of‐Function Alterations and Their Association with the Focal Tandem‐Duplicator Phenotype
- (2019) Ethan S. Sokol et al. ONCOLOGIST
- LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
- (2019) M R Smith et al. ANNALS OF ONCOLOGY
- Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
- (2019) Vivek L. Patel et al. CANCER RESEARCH
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
- (2019) Lisanne F. van Dessel et al. Nature Communications
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Genomic Markers in Prostate Cancer Decision Making
- (2018) Vito Cucchiara et al. EUROPEAN UROLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
- (2018) Emmanuel S. Antonarakis NEW ENGLAND JOURNAL OF MEDICINE
- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC.
- (2017) Karen A. Autio et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- Non-homologous end joining: advances and frontiers
- (2016) Kai Yang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eukaryotic Mismatch Repair in Relation to DNA Replication
- (2015) Thomas A. Kunkel et al. Annual Review of Genetics
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
- (2015) Elena Castro et al. EUROPEAN UROLOGY
- Error-Prone Repair of DNA Double-Strand Breaks
- (2015) Kasey Rodgers et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
- (2014) Elizabeth K. Bancroft et al. EUROPEAN UROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started